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1. Introduction 
Cystic fibrosis (CF) – or mucoviscidosis – is a common autosomal recessive inherited 
disease, affecting the whole body and causing progressive deficiencies. The name ‘cystic 
fibrosis’ refers to the characteristic scarring (fibrosis) and formation of cysts in the pancreas. 
The first anatomical and pathological description of the disorder was done by Landsteiner 
in 1905. In 1936, Fanconi et al. identified it as an autonomous illness, and in 1994 Farber et al. 
named it mucoviscidosis, due to the thick and viscous mucus secreted by the exocrine 
glands. It is accounted for by several clinical manifestations. Respiratory impairment is the 
most serious symptom (resulting from chronic infection in the lungs) and, though it is 
treatable, it is resistant to antibiotics and other medication. The large number of other 
symptoms include sinusitis, inadequate growth, diarrhoea and infertility, each of which is 
an effect of CF in other parts of the body. The mutated gene is transmitted by father and 
mother – although it may be that neither of them manifest the disease –  and it is accounted 
for by the change in carrying ions through the membranes of the cells (Quinton et al., 1983). 
This compromises the function of the exocrine glands that produce thicker and hard-
eliminating substances (mucus, sweat or pancreatic enzymes). 
In 1953, Di Sant’Agnase et al. noted an increased sodium chloride rate eliminated through 
the sweat of patients with CF. Gibson and Cooke (1958) standardised the sweat test, which 
has become an important tool in the diagnosis of the disease. In 1958, Shwachman and 
Kulczucki designed a disease-severity assessment system. In 1985, the position of the CFTR 
gene was determined on the long arm of chromosome 7, q31 band, by restriction fragment 
linked polymorphism (Knowlton et al., 1985), and, in 1989, the  full-length gene was 
sequenced (Collins, 1992). 
The clinical manifestations of CF are primarily due to the obstruction of the ducts of organs 
(such as the lung and the pancreas) by thick, viscous secretions, changes in electrolytic 
concentrations, and the presence of abnormal contents. The primary cellular defect consists 
of a decreased or else absent expression of the CF transmembrane conductance regulator 
(CFTR) protein, which causes changes in chloride secretion. This protein is present in all 
endodermal and mesodermal cells, and it has been found in sweat glands, organs of the 
digestive system, and the airways’ epithelium layer (Bargon et al., 1999). The primary defect 
causes dehydration of the airways, leading to an increased viscosity of mucus in the 
intercellular environment, and it predisposes the body to chronic bacterial infections 
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(Tummler et al., 1999). At birth, the lung is histologically normal, and the 
pathophysiological changes evolve with aging (Shwachman et al., 1970). CF leads to 
pulmonary bronchiectasis and atelectasis, compromising the bronchi and bronchioles and so 
causing pulmonary emphysema. The pancreas is the organ that presents the largest 
functional and structural changes (Rozov et al., 1991). The blockage of glandular ducts leads 
to malnutrition syndrome, biliary liver cirrhosis, intestinal obstruction, and 
gastroesophageal reflux. In newborn infants, the presence of ileum-meconium can mark the 
first manifestation of CF (Feingold et al., 1999). Exocrine insufficiency of the pancreas occurs 
in 95% of cases (Mousia-Arvanitakis, 1999) and results in a decrease or the absence of 
lipolytic, proteolytic and amylolytic enzymes in the pancreatic juice, leading to chronic 
diarrhoea with bulky, greasy and fetid faeces. As a result, malnutrition becomes evident, 
owing to the loss of calories and proteins through poor digestion (Reis e Damasceno, 1998). 
The blockage can also affect the biliary ducts – the thick bile leads to difficulties of drainage, 
and there may be a full blockage of the ducts which may evolve into cirrhosis (Kopel, 1992). 
Advances in genetic engineering and the development of transgenic animals during the last 
decade of the twentieth century, in conjunction with the prospect of early diagnosis, has 
contributed to the provision of proper and effective treatments that can increase the quality 
of life of patients with CF. 
1.1 Incidence 
The incidence of CF varies according to ethnicity, ranging from 1 CF individual per 2,000 to 
5,000 Caucasian live births in Europe, the United States and Canada, 1 CF individual per 
15,000 African Americans, and from 1 CF individual per 40,000 live births in Finland 
(Brunechy, 1972). In Brazil, the estimated incidence for the southern region is closer to that 
of Central Europe’s Caucasian population, whereas for other regions it reduces to 1 per 
10,000 live births. This is despite the fact that there are variations in the frequency of 
mutations in different geographic regions, which would probably reflect a different 
prevalence of the disease (Raskum et al., 1993). In the US and in European countries, early 
diagnosis – before the first year of life – allows affected children to be promptly treated and 
monitored with regard to the variables that directly influence the prognosis of the disease, 
such as the follow-up of the weight and height curve, and the presence of upper airway 
colonisation by pathogens (which is closely related to worse prognosis). 
In Brazil, since 2001, and with the approval of the National Newborn Screening Program 
and its introduction by the laboratory of the Ecumenical Foundation for Exceptional 
Protection (FEPE-PR, Portuguese acronym), CF screening has been implemented in the State 
of Parana. Before the establishment of the National Newborn Screening Program for CF, the 
data showed that the average age receiving a diagnosis of the disease ranged at around 1.6 
years (Santos et al., 2005). 
1.2 Genetics 
The isolation of the CFTR is a result of many years of study on the part of numerous 
research groups. Situated in long arm of the chromosome 7, at band q31.3 (Heng et al., 1993), 
with 250 Kb, the region codifier of the CFTR consists in 27 exons. Most of the exons are far 
from one another by between 50 and 250 base pairs, except for exon 13 which has 723 base 
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pairs of the genomic DNA. The CFTR protein has a molecular weight of 168,138 Da and it 
belongs to a transmembrane chloride ion channel superfamily protein, with 1,480 amino 
acids (Harris, 1992) present in apical membranes of those cells lining the surface of  the 
gland tubes and the airways. 
About 1,500 mutations have already been identified in the CFTR: the most frequent 
mutation is F508del, which is found in 30% of patients with CF (Zielenski, 2000). This 
mutation is caused by the deletion of three base pairs corresponding to the codon that 
translates a residue phenylalanine at position 508 of the CFTR polypeptide chain (Morral, 
1994). Depending on ethnic groups in different geographic locations the relative frequency 
of this mutation vary among individuals affected by CF. In Northern Europe and North 
America, it reaches 70-90%; however it is less frequent in Southern Europe, where less of 
50% of the CF chromosomes have this mutation (Morral et al., 1994). 
The G542X mutation is considered to be the second most frequent mutation, and it accounts 
for 3.4% of alleles in CF (Tsui, 1992). At a molecular level, it leads to a replacement of 
nucleotides, which results in a stop codon at position 542 of the polypeptide chain, and thus 
the translation product is a non-functional peptide that will be degraded. According to the 
geographic location, the frequency of this mutation varies among the CF individuals. It may 
be found in the compound heterozygous with the ∆F508 mutation. Raskin et al. (1993) have 
noted the frequency of the G542X mutation in 5% of the Brazilian population. 
The G551D mutation affects 2.4% of the chromosomes of the population of individuals with 
CF – in general – and it leads to a replacement of guanine for adenine in nucleotide 1784 
and, as with the G542X mutation, it also is located in exon 11. In Brazil, it presents a 
frequency of 1% (Raskin et al., 1993). Other, less frequent, mutations include: W1282X, 
N1303K, R553X, R1162X, and R334W (with their incidence varying according to population). 
Table 1 shows the molecular changes, and consequences of the more common mutations in 
the cystic fibrosis gene (Tsui, 1992). 
1.3 Treatment 
Approximately 50% of affected individuals are diagnosed in the age range from zero to six 
years but this percentage goes to 90% for those aged zero to eight years. Since reinforced 
nutrition is associated with a better prognosis, the screening of newborn infants is indicated. 
CF is one of most studied genetic diseases under the new therapy approaches, such as gene 
therapy which aims to restore the CFTR function. Clinical trials of gene therapy have been 
performed with viral vectors and cationic lipids. Despite advances in our knowledge of the 
disease, there is no specific treatment for CF yet. Due to its multi-systemic and chronic 
character, its treatment should be performed in reference centres and with a 
multidisciplinary team. Patients responding well to the treatment showed a median survival 
which has been increasing year to year, from over two years in 1950 up to between thirty 
and forty years today (Ribeiro et al., 2002). It is necessary to establish a strong and 
uninterrupted treatment program which is addressed to the prophylaxis of infections and 
complications. It should be started as soon as possible and it should be individualised, 
taking into account its severity and the organs affected. Early treatment decreases the 
evolution of the pulmonary lesions, improves prognosis, and increases the chances of 
survival. 
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NAME MUTATION CONSEQUENCE 
ΔF508 Deletion of 3pb between 1652 
and 1655 of the exon 10 
Deletion of Phe in codon 508 
G542X G→T in nt 1756 of exon 11 Gly→ stop code in codon 542 
G551D G→A in nt 1784 in exon 11 Gly→ Asp in codon 551 
W1282X G→A in nt 3978 of exon 20 Trp→ stop code in codon 1282 
3905insT 
Insertion of T after the nt 3905 of 
exon 20 
Change the reading chart. 
N1303K C→G in nt 4041 of exon 21 Asn→Lys in codon 1303 
3849+10kbC → T C→T in a Eco RI fragment at the 
attachment 5’ of intron 19 
ABERRANTE excision 
R553X C→T in nt 1789 of exon 11 Arg→ stop code in codon 553 
621+1G→T G→T in nt 1 of attachment 5’ of 
intron 4 
Excision mutation 
1717-1G→A G→A in nt 1 of attachment 3’ of 
intron 10 
Excision mutation 
1078delT Deletion of T in nt 1078 of exon 7 Change reading chart 
2789+5G→A G→A in nt 5 of end 5’ of intron 
14b 
Excision mutation 
3849+4A→G A→G in nt 4 of end 5’ of intron 
19 
Excision mutation 
711+1G→T G→T in nt 1 of attachment 5’ of 
intron 5 
Excision mutation 
R1162X C→T in nt 3616 of exon 19 Arg→ stop code in codon 1162 
1898+1G→A G→A in nt 1 of attachment 5’ of 
intron 5 
Excision mutation 
R117H G→A in nt 482 of exon 4 Arg→His in codon 117 
3659delC 
Deletion of C in nt 3659 of exon 
19 
Change the reading chart 
G85E G→A in nt 386 of exon 3 Gly→Glu in codon 85 
2184delA 
Deletion of A in nt 2184 of exon 
13 
Change the reading chart 
Δ1507 Deletion of 3pb between nt 1648 
and 1653 of exon 10 
Deletion of IIe at codon 506 or excision 
mutation 
R347P G→C in nt 1772 of exon 7 Arg→Pro in codon 347 
R560T G→C in nt 1811 of exon 11 Art→Thr in codon 560 or excision 
mutation 
A455E C→A in nt 1496 of exon 9 Ala→Glu in codon 455 
R334W C→T in nt 1132 of exon 7 Arg→Trp in codon 334 
S549R(T→G) T→G in nt 1779 of exon 11 Ser→Arg in codon 549 
Q493X C→T in nt 1609 of exon 10 Gln→ stop code in codon 493 
S549N G→A in nt 1778 of exon 11 Ser→Asn in codon 549 
Table 1. Table obtained from Tsui (1992). 
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Pseudomonas aeruginosa has been found in more than 80% of teenagers with CF (Dubouix et 
al., 2003). Once established in the airways, the Pseudomonas aeruginosa infection is not 
eradicated by antibiotics, which only reduce the number of the colonies of bacteria. In order 
to treat CF, antibiotics can be administered through oral, intravenous or inhalation routes – 
the choice of which route should be made according to demand, prophylaxis and 
maintenance. 
Ribeiro et al. (2002) defined the main objective of the treatment of CF, namely: the continued 
education of patients and their relatives concerning the disease; prophylaxis of the infections 
with a full vaccination program; early detection and control of pulmonary infection; 
respiratory physiotherapy and the improvement of bronchial blockage; the correction of 
pancreatic insufficiency; nutritional support with guidelines for diet and vitamin 
supplementation; monitoring the progress of the disease and any complications; family 
genetic counselling; finally, the provision of any information to patients and relatives 
concerning any advances in knowledge of CF. 
1.4 Genetic counselling 
Genetic counselling is essential in order to improve the understanding of the medical, 
psychological and familial implications of the disease. This process consists of the following 
steps: the interpretation of the familial medical history so as to assess the possibility of any 
occurrence or recurrence of the disease; the provision of education on heredity, genetic tests, 
the management of the disease, prevention, resources and research; the offer of counselling 
so as to properly inform the patient of the risks of having an affected child and its future life 
chances (Resta et al., 2006). Thus, counselling involves confirmation of the diagnosis, the 
estimated risk of recurrence, the provision of information about the disease, offers of 
support, and assistance with the acceptance of the diagnosis. It also suggests the provision 
of proper treatment and the offer of alternatives for prevention, such as pre-natal diagnosis 
and pre-implantation diagnosis. The first step for effective genetic counselling is the 
confirmation of the diagnosis of the affected individual (Harper, 2000). The definitive 
diagnosis of the disease is done with clinical features and the increased concentration of 
electrolytes (chloride and sodium) in sweat. The presence of the disease may be supposed 
from an altered neonatal screening, before the onset of symptoms. The CF hereditary pattern 
is autosomal recessive (i.e. in order to manifest the disease, the individual should present a 
mutation in two of the alleles of the CFTR). Therefore, both of the parents of the affected 
individual are carriers (heterozygous), and the risk of the recurrence of a CF child at birth is 
25%. The individual with CF may show the same mutation in both of the alleles 
(homozygous for certain mutations) or else different mutations in each of the alleles 
(compound heterozygous). Healthy individuals carrying the mutation in only one of the 
alleles are called heterozygous (Saraiva-Pereira et al., 2011). 
With the increase in the life expectancy of CF patients, many women carrying the disease 
have had pregnancies, whereas the affected men had shown infertility secondary to the 
obstructive azoospermia; nonetheless they may also have children because of assisted 
reproduction techniques.  The risk of a CF individual having affected children depends 
upon her/his partner – if the partner is a carrier of the disease, that risk is 50%. The 
frequency of carriers for CF within the general population varies according to ethnic origin. 
In Caucasian populations, the frequency of heterozygous varies from 1/25 to 1/30 
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individuals (Saraiva-Pereira et al. 2011). The main difficulties for the genetic counselling of 
CF are those cases in which clinical confirmation is uncertain or else those cases in which is 
not possible to detect carriers within the family. 
2. CF and infertility 
2.1 Clinical features of infertility in CF 
CF is a genetic disorder caused by mutations in the Cystic Fibrosis Transmembrane 
Regulator (CFTR) gene (Kerem et al., 1989; Riordan et al., 1989; Rommens et al., 1989). The 
CFTR is an anion channel regulated by cAMP-dependent phosphorylation, and it is 
expressed in the apical membrane of epithelial cells of a wide variety of tissues, including 
the reproductive tracts. The physiological role of CFTR in reproduction and its involvement 
in the pathogenesis of reproductive diseases remains largely unknown (Chan et al., 2009). 
The CF disorder is characterised by altered chloride and the bicarbonate transport of 
secretory epithelial cells (Chan et al., 2006; Li et al., 2010; Quinton, 1990, 1999). 
Approximately 97% CF men are sterile due to the congenital bilateral absence of the vas 
deferens (CBAVD) and obstructive azoospermia (Wong, 1998). It has been suggested that 
the absence of vas deferens might be related to the requirement of the CFTR function at the 
embryonic stage (Li et al., 2010). It was demonstrated that the expression of the CFTR is 
developmentally regulated: cultured epithelial cells from the human foetal vas deferens 
have been shown to express the CFTR (Harris et al., 1991). Therefore, it is conceivable that 
fluid secretion by the Wolffian duct is required for the normal development of vas deferens. 
When secretion is impaired in CF individuals, normal development might be interrupted 
and so lead to vas agenesis (Wong, 1998). 
Clinically, CF patients present a spectrum of genital phenotypes ranging from normal 
fertility to severely unpaired spermatogenesis and CBAVD (Xu et al., 2007). The diagnosis of 
CBAVD is based on the presence of azoospermia in subjects with normal or small size testes, 
non-palpable vas deferens, the characteristic ultrasonography view, and changes in the 
physical and biochemical properties of ejaculate (Jarzabek et al., 2004). Male CF patients’ 
semen is characterised by azoospermia, low volume, low or normal viscosity, and increased 
turbidity. Testicular specimens show active spermatogenesis, although 50% of the 
spermatozoa have malformed heads. The pre-meiotic spermatogonia in CF patients appear 
to be morphologically normal, whereas the post-meiotic spermatogenic stages show 
malformation or the impairment of nuclear division (Denning et al., 1968). Testicular 
biopsies of post-pubertal men with CF have shown abnormal histological findings, such as 
pathological spermatogenesis and an increased number of dysmorphic spermatozoa (Mak et 
al., 2000). 
The investigation of CFTR expression in male reproductive tissues showed that CFTR was 
present in the epididymis and vas deferens throughout post-natal life. High levels of CFTR 
expression were found in the head of the epididymis, but a variable expression was seen in 
distal epididymis. No CFTR was detected in the human testis. Accordingly, it was suggested 
that the anomalies in spermatozoa described in CF adult patients may result from 
epididymal dysfunction (Tizzano et al., 1994). Primary cultures of rat epididymal epithelial 
cells demonstrated the functional expression of CFTR and its involvement in the regulation 
of chloride secretion and fluid formation in the epididymis (Wong, 1998). Under basal 
www.intechopen.com
 
Cystic Fibrosis and Infertility 
 
73 
conditions, the epididymis generally reabsorbs fluid to concentrate sperm. However, the 
observation that neurohormonal factors stimulate CFTR-mediated chloride secretion by 
epididymal epithelia (Wong, 1998) suggests that epididymal fluid secretion may be 
stimulated so as to create the optimal fluid environment for sperm maturation, storage, and 
even transport during ejaculation (Chan et al., 2009). Approximately 18 % of non-clinical CF 
men with infertility due to a reduction of sperm quality, and 15 % men with azoospermia, 
have at least one mutation in the CFTR. The frequency of mutations in infertile males 
presents a significantly higher than expected 4 % of the CF carrier frequency within the 
population. This increased frequency of CFTR mutations in healthy men with reduced 
sperm quality, and in men with azoospermia without CBAVD, suggests that the CFTR 
protein might be involved in the process of spermatogenesis or sperm maturation, over and 
above playing a critical role in the development of the epididymal glands and the vas 
deferens (Van der Ven et al., 1996). 
In order to fertilise eggs, mammalian sperm must acquire fertilising potential in the female 
reproductive tract through a process known as capacitation. Sperm capacitation is a 
prerequisite for the acrosome reaction, which is an exocytotic event releasing hydrolytic 
enzymes from the acrosome so as to enable spermatozoa to penetrate the egg investments 
and its plasma membrane (Jarzabek et al., 2004; Xu et al., 2007). Capacitation is associated 
with the elevation of intracellular pH and the hyperpolarisation of the sperm plasma 
membrane (Meizel & Deamer, 1978; Zeng et al., 1995). These events depend on extracellular 
bicarbonate, which activates adenylyl cyclase pathway producing cyclic adenosine 
monophosphate (cAMP) and various downstream cellular events (such as protein tyrosine 
phosphorylation) and results in sperm capacitation (Demarco et al., 2003; Xu et al., 2007). 
As has been shown, CFTR secretes bicarbonate in the uterus and sperm, and its 
impairment leads to reduced sperm capacitation and the fertilising capacity of sperm 
(Wang et al., 2003; Xu et al., 2007). The interaction of the CFTR protein with its inhibitor or 
antibody significantly reduces sperm capacitation and associated bicarbonate-dependent 
events, including increases in intracellular pH, cAMP production, and membrane 
hyperpolarisation. The fertilising capacity of the sperm obtained from heterozygous CFTR 
mutant mice is also significantly lower compared with the wild-type. These findings 
suggest that sperm CFTR may be involved in the transport of bicarbonate important for 
sperm capacitation, and that CFTR mutations causing impaired CFTR function may lead 
to a reduced sperm fertilising capacity and male infertility other than CBAVD (Xu et al., 
2007). A recent study showed that human sperm capacitation as facilitated by 
progesterone and acrossome reactions induced by recombinant human zona pellucida 3 
peptides (rhuZP3) were both significantly inhibited by a CFTR inhibitor. In a group of 
fertile men, the percentage of spermatozoa expressing CFTR was significantly higher than 
that of the healthy and infertile men’s group. In addition, the study showed that the 
presence of a CFTR inhibitor markedly depresses intracellular cAMP levels, sperm 
hyperactivation and the sperm penetration of zona-free hamster eggs (Li et al., 2010). 
Moreover, when spermatozoa from CF patients with CBAVD are used for 
intracytoplasmic sperm injection, fertilisation rates are not reduced, suggesting a specific 
defect in zona pellucid penetration or membrane fusion capacity in these spermatozoa 
(Silber et al., 1994; Li et al., 2010). CFTR appears to have a profound role in regulating 
sperm function (Chan et al., 2009). 
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In CF female patients, the cause of reduced fertility remains obscure. CFTR is expressed 
throughout the female reproductive tract in the cervix, oviduct, ovary, and uterus (Chan et 
al., 2002; Tizzano et al., 1994). CF has been associated with menstrual irregularities, 
including amenorrhea, irregular cycles, anovulation, smaller uteri, and delayed puberty 
(Johannesson et al., 1998; Stead et al., 1987). The absence of obvious anatomical 
abnormalities in the female reproductive tract – except for thick and tenacious cervical 
mucus with altered water and electrolyte content (Kopito et al., 1973) – has led to the general 
belief that abnormal mucus contributes to the reduced fertility of CF women by acting as a 
barrier to sperm passage (Chan et al., 2009). However, repeated and unsuccessful attempts 
with intrauterine insemination were also reported (Epelboin et al., 2001; Rodgers et al., 
2000), suggesting that further abnormalities (such as inadequate fluid control throughout 
the rest of the reproductive tract) could also contribute to infertility in humans (Hodges et 
al., 2008). 
As already noted, CFTR plays a crucial role in mediating uterine bicarbonate secretion and 
sperm capacitation, leading to the thought that CFTR bicarbonate secretion dysfunction 
might induce an impaired sperm fertilising capacity and reduced fertility in CF women. In a 
mouse sperm-endometrial epithelial cell co-culture system, it was demonstrated that 
endometrial epithelial cells possess a CFTR-mediated bicarbonate transport mechanism. A 
substantial decrease in apical fluid bicarbonate contents was observed after treatment with 
both blockers of CFTR and antisense oligonucleotides against CFTR when compared with 
the control. These results are consistent with the CFTR’s mediating uterine bicarbonate 
secretion, and they indicate that defective CFTR might lead to impaired bicarbonate 
secretion in the uterus. In vitro fertilisation assays on zona-intact mouse eggs further 
demonstrated that the number of two-cell embryos obtained with sperm capacitated in a 
conditioned medium from CFTR antisense-treated endometrial cells was significantly 
reduced as compared with that obtained from sense-treated controls. Sperm capacitation 
and egg-fertilising ability depend – critically – on CFTR and bicarbonate content and 
defective CFTR-mediated bicarbonate secretion, and the lower fertilising capacity of sperm 
might also account for lower CF female fertility (Chan et al., 2009; Wang et al., 2003). 
CFTR expression in the uterus is regulated by ovarian hormones with increasing expression 
in response to estrogen and decreasing expression in response to progesterone; this is a 
pattern that correlates with cyclic changes in uterine fluid (Zheng et al., 2004). Hormone 
changes have been observed in CF female adolescents, who displayed reduced estradiol and 
FSH levels (Reiter et al., 1981), and CF female adults, who displayed increased testosterone 
and reduced estradiol and progesterone levels, compared with age-matched controls 
(Johannesson et al., 1998). Interestingly, through observations in rodent uterus, CFTR was 
found to be co-expressed with the epithelial sodium channel (ENaC) in an out-of-phase 
fashion. With the maturation of ovarian follicles and the estrogen secretion phase, CFTR is 
highly expressed and ENaC is poorly expressed. Inversely, with corpus luteum activity and 
progesterone secretion, low CFTR expression and high ENaC expression are observed 
(Chan et al., 2002). This may explain maximal fluid secretion during the early phase of the 
oestrous cycle, when the level of oestrogen is at its highest. Similarly, at dioestrus, the 
attenuated fluid production with down-regulation of CFTR and increased reabsorption by 
up-regulation of ENaC may account for the disappearance of uterine fluid. These cyclic 
changes in CFTR and ENaC expression which result in uterine fluid volume variation have 
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physiological significance. Maximal CFTR expression and – therefore – high uterine fluid 
production may lubricate the cervical and vaginal lumen for sperm movement towards the 
oviduct as well as sperm capacitation. Equally, low CFTR expression and – consequently – 
reduced fluid volume may enhance close contact on the endometrial surface, facilitating 
embryo implantation. Dynamic changes in the fluid microenvironment, particularly the 
fluid volume, in the female reproductive tract are dictated by CFTR expression, which is 
normally regulated by ovarian hormones throughout the cycle and accommodating various 
reproductive events. The impairment of CFTR expression may lead to the disturbance of the 
fluid environment, resulting in various pathological conditions and infertility (Chan et al., 
2007; Chan et al., 2009). 
Interestingly, abnormalities in the reproductive endocrine axis have been viewed as an 
indirect consequence of CF, though they have been largely ignored as possible contributors 
to observed female infertility (Stead et al., 1987). CFTR expression was found in the areas of 
the rat hypothalamus (thalamus and amygdale) which are involved in the regulation of 
sexual maturation and reproduction. CFTR might increase the acidification of synaptic 
vesicles, and thus play an important role in the central regulation of sexual maturation and 
fertility (Johannesson et al., 1997b). Delayed pubertal increments of serum gonadotropin and 
sex hormone levels in CF patients suggest a late maturation of the reproductive system 
(Reiter et al., 1981). Anovulatory women showed significantly lower luteal oestradiol and 
progesterone, but higher total testosterone concentrations when compared to healthy 
controls and the ovulatory CF women (Johannesson et al., 1998). In a mouse model, 
increased FSH levels were found in CFTR mutant females as a result of a decreased number 
of ovulatory follicles, leading to less estradiol production and a lack of feedback inhibition 
of FSH secretion. CF female mice exposed to exogenous hormones showed a correction of 
organ size and ovulation. These findings suggests that the CF reproductive organs can 
respond to gonadotropins, but that an impaired hypothalamic-pituitary-gonadal (HPG) axis 
may be a direct cause of reduced fertility in women with CF (Hodges et al., 2008; 
Johannesson et al., 1997b). 
In CF women, late puberty and amenorrhea are common clinical findings due to the deficit in 
their nutritional status. It has also been suggested that the lack of ovulation is a consequence of 
malnutrition and catabolism. Clinically, the anovulatory women presented more profound 
essential fatty acid deficiency (EFAD) and hypersecretion of insulin during an oral glucose 
tolerance test compared to the ovulatory women (Johannesson et al., 1998). However, it was 
shown that menarcheal age was also delayed in CF females in good clinical and nutritional 
condition. Homozygous patients for the most common mutation – F508del – and those with a 
pathological glucose tolerance test (OGTT) showed the most delay in menarcheal age 
(Johannesson et al., 1997a). This may be explained by the fact that ovarian cells express insulin 
receptors that mediate gonadal steroid production. Experimental data has shown that insulin 
has a gonadotropic effect through different mechanisms, such as a direct effect on 
steroidogenic enzymes, the modulation of FSH or LH receptor number, synergism with FSH 
and LH, and nonspecific enhancement of cell viability (Porestky & Kalin, 1987). Insulin 
appears to be necessary for the ovary to reach its full steroidogenic potential. The difference 
observed in the insulin pattern in the pathological OGTT group might alter ovarian function 
and thereby cause further delay in sexual maturation (Johannesson et al., 1998). Polycystic 
ovaries were also described in CF women (Stead et al., 1987). 
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CFTR mutations were previously associated with Congenital Absence of Uterus and Vagina 
(CAUV). CF mutations might affect the normal embryological development of the Müllerian 
ducts. During the seventh week of gestation, the cranial end of the Müllerian duct is 
immediately adjacent to the Wolffian duct, and both ducts share a common basement 
membrane. The Wolffian duct then guides the caudal growth of the Müllerian ducts. By the 
ninth week of gestation, the Müllerian duct reaches the caudal end of the adjacent Wolffian 
duct. At this time, these ductal systems separate from each other, form separate basement 
membranes, and continue to develop independently (Ludwig, 1998). The interdependency 
of these two systems suggests that the same genetic factors may control the early 
development of both systems. Failure of the development of the Müllerian duct causes 
CAUV in females. The incidence of most common CFTR mutations found in patients with 
CAUV (8%) is twice that which is found in the general population (4%), but much less than 
the incidence of CFTR mutations in men with CBAVD (80%). This suggests that it is unlikely 
for CFTR mutations to cause CAUV in females as they cause CBAVD in some males. As 
such, the effect of the abnormal CFTR protein product on the Wolffian duct must occur at a 
time when the development of the Müllerian duct is no longer dependent on the Wolffian 
duct (Timmreck et al., 2003). 
CF female patients have such pregnancy complications as premature labour and delivery 
and increased maternal and prenatal mortality due to severe maternal pulmonary infection 
and maternal weight loss (Cohen et al., 1980; Kent & Farquharson, 1993). However, the risk 
of the deterioration of health during pregnancy for females with CF is considered to be 
small, if good medical care is provided and if women are in a stable and good clinical 
condition (FitzSimmons et al., 1996). 
There remain many unanswered questions as to the cause of infertility in CF, and the exact 
role of CFTR in reproductive physiology and the contribution of CFTR dysfunction to 
infertility in both sexes is far from understood (Chan et al., 2009). 
2.2 CFTR mutations closely related to CF infertility 
Infertility, or at least subfertility, in males with CF was first suspected in the 1960s (Denning 
et al., 1968; Radpour et al., 2008). Depending upon their molecular consequences, CFTR 
mutations may result in either a typical CF or else an atypical (often monosymptomatic) CF, 
such as congenital absence of the vas deferens (bi- or unilateral), bilateral ejaculatory duct 
obstruction, or bilateral obstructions within the epididymis (Jarzabek et al., 2004). 
Approximately 80% of CF male patients present CBAVD, a Wolffian duct anomaly 
(Radpour et al., 2008). Male infertility due to CBAVD has been shown to be commonly 
linked to CFTR mutations, and it is considered to be a genital form of CF or a CFTR-
associated disease with incomplete CF expression (Dequeker et al., 2009; Kanavakis et al., 
1998; Rave-Harel et al., 1997). Men with CBAVD are apparently healthy, with relatively 
normal lung and pancreatic functions. CBAVD appears to be a heterogeneous genetic 
condition, with many cases being mild forms of CF (DeBraekeleer and Férec, 1996). 
Extensive studies have shown that patients with isolated CBAVD carry two CFTR 
mutations, usually in compound heterozygosity (Chillón et al., 1995; Claustres et al., 2000). 
Of isolated CBAVD patients, where the mutation is found on both CFTR, about 88% carry 
one severe mutation and one mild mutation, whilst the remaining 12% carry mild mutations 
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on both CFTR (Claustres et al., 2000). This is in contrast to classical clinically CF patients, 
where about 88% of the CF patients carry severe mutations on both CFTR, whilst about 11% 
carry a severe mutation on one CFTR and a mild mutation on their second one (Claustres et 
al., 2000; Radpour et al., 2008). The most frequent CFTR mutation conferring a mild 
phenotype found in CBAVD patients is the 5T polymorphism (Chillón et al., 1995), which is 
an allele found at the polymorphic Tn locus in intron 8 of the CFTR, and which can be found 
as a stretch of 5, 7, or 9 thymidine residues at this locus. Less efficient splicing will occur 
when a lower number of thymidines are found, resulting in CFTR transcripts that lack exon 
9 sequences (Chu et al., 1993; Radpour et al., 2008). Men with the 5T variant in the non-
coding region of the gene will produce an abnormally low level of CFTR protein in the 
epididymis. However, there may be sufficient proteins for the prevention of disease in other 
organs (such as the lung and the gastrointestinal glands) normally affected by CF, which 
might explain why the lung and pancreas are normal in CBAVD, but the epididymis is not 
(DeBraekeleer and Férec, 1996; Jarzabek et al., 2004; Wong, 1998). The analysis of the level of 
correctly spliced RNA transcribed from the 5T allele in different tissues (nasal and 
epididymal epithelium) and its correlation with CF disease expression, has shown that in 
infertile males with normal lung function the level of correctly spliced transcripts found in 
the nasal epithelium was higher than the level found in the epididymal epithelium. It 
indicates that there is variability in the efficiency of the splicing mechanism  both between 
different individuals and between different organs of the same individual. In many human 
monogenic diseases, high variability in disease expression is found among patients carrying 
the same genetic defect (Levy et al., 2010; Rave-Harel et al., 1997). The molecular basis for 
this variability has been suggested to be allelic heterogeneity, additional genetic loci, and/or 
environmental factors. Accordingly, allelic variants of genes involved in the splicing 
regulation might contribute to the different efficiencies of alternative splicing found 
amongst different individuals (Rave-Harel et al., 1997). 
CFTR mutations may represent one of the most common abnormalities associated with 
male infertility, especially with CBAVD but also with obstructive azoospermia (Kanavakis 
et al., 1998). A screening of the entirety of the CFTR in males with CUAVD (congenital 
unilateral absence of vas deferens), CBAVD and obstructive azoospermia of the vas 
deferens, has shown that almost 64% of patients carry two CFTR mutations. The most 
frequent mutations observed amongst those patients were F508del (44.7%), T5 allele 
(36.2%), and R117H (19.1%) (Jézéquel et al., 2000). In a large French cohort study, the most 
frequent allele mutations identified in CBAVD male patients were F508del (21.7%), the 5T 
allele (16.3%) and R117H (4.4%), followed by D1152H (1.19%) and D443Y (0.93%). Two 
CFTR mutations (including the 5T allele) were present in 47.7% and one mutation in 
24.6% of CBAVD patients, while no mutation was reported in the remaining 27.7%. 
Approximately 43.5% of patients with CBAVD carried one F508del allele, and 31.7% had 
at least one 5T allele. Altogether, at least one CFTR mutation was identified in 72.25% 
individuals with CBAVD (Claustres et al., 2000). In an Italian multicentric study, a 
molecular screening of the most common CFTR mutations in infertile couples was 
performed. CFTR mutations were detected in 4.6% of subjects, a percentage that overlaps 
with the general population carrier frequency. However, it was found a mutation-
frequency of over 37% amongst CBAVD individuals and of 6% in males with non-
obstructive azoospermia (Stuppia et al., 2005). In another study, the carrier status of 
CBAVD patients for the F508del mutation was screened and 57% were found to be 
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carriers. Amongst these patients, 25% were later found to have compound heterozygotes 
for the F508del and R117H mutations (Williams et al., 1993). A study of the entire coding 
region of the CFTR of CBAVD patients found that 28.6% have mutations in both copies of 
the CFTR, 42.8% had one CFTR mutation, whilst in the remaining 28.6% no CFTR 
mutations were found (Kanavakis et al., 1998). These figures give an average of an eleven-
fold increase of the carrier frequency compared to the population data on CFTR mutations 
in CBAVD patients. (Uzun et al., 2005). Amongst cases of obstructive azoospermia, 30% 
had one CFTR mutation whilst in the remaining 70% no mutations were found – this 
indicates an association between cases of obstructive azoospermia without CBAVD with 
CFTR mutations. The frequency of the IVS8(5T) allele was 14.3% for the CBAVD cases, 
which was three-fold higher than for normal chromosomes (Kanavakis et al., 1998). 
Similarly, another extensive analysis of the CFTR in CBAVD patients revealed that 42% of 
subjects were carriers of one CFTR allele and that 24% were compound heterozygous for 
CFTR alleles. The presence of only one CF allele in approximately 42% of CBAVD patients 
implies some role on the part of CF in CBAVD, although additional factors or genes are 
necessary for the development of CBAVD in those patients (Mercier et al., 1995; Van der 
Ven et al., 1996; Williams et al., 1993). The CFTR mutations commonly associated with 
male infertility are F508del, R117H, and the IVS8 (5T) polymorphism, each of which 
exhibit diverse frequencies among different cohorts (Van der Ven et al., 1996). Since the 
spectrum of CFTR mutations is markedly different amongst populations, the ethnic 
background of the patients should be taken into account so as to ensure that the most 
prevalent mutations appropriate to that particular population are included in the 
screening panel (DeBraekeleer & Férec, 1996). Altogether, the mutation-frequencies in 
infertile male patients are significantly higher than the expected carrier-frequencies in the 
general population (Van der Ven et al., 1996). 
There are only a few studies on female CFTR mutation-frequency in the literature. It is 
generally assumed that fertility is reduced in CF women, although not as dramatically as in 
men. It was already proposed that CFTR mutations do not appear to be involved in female 
infertility (Morea et al., 2005) and CAUV condition (Radpour et al., 2008). The most common 
CFTR mutations – including the 5T allele – were tested in isolated CAUV female patients. 
These mutations were only found in 8% of the subjects, suggesting that it is unlikely that 
CFTR mutations cause CAUV in females (Timmreck et al., 2003). In a recent study, 24 
women with altered fertility were screened for the F508del mutation. Amongst them, 37.5% 
showed reduced fertility without a known cause, 20.8% presented reduced fertility due to 
polycystic ovarian syndrome (although two of them demonstrated malformations of the 
reproductive tract), 37.5% had been pregnant previously although most of them had 
spontaneous abortions, and 8.3% presented early menopause. It was found that one patient 
who was a F508del mutation carrier and who had had an early menopause had also had a 
previous abortion. Unexpectedly – considering that Brazilian population is greatly mixed – 
the carrier frequency for the most common mutation in CF amongst infertile Brazilian 
women was similar to that of Caucasian populations. It was proposed that there are 
common clinical features between women with altered fertility and with CF women, and 
that CF mutations may be more frequent than expected amongst patients with fertility 
issues (Brunoro et al., 2010). Large cohort studies on CFTR mutation-frequency among 
infertile women are needed. 
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2.3 Considerations for CF mutation screening tests 
According to the CF Mutation Database, around 20 mutations have individual 
worldwide frequencies greater than 0.1%, and can thus be considered to be common 
mutations (Lay-son et al., 2011). These common mutations vary by geographic and/or 
ethnic origin. Latin American countries have a high ethnic admixture and they show a 
wide distribution of 89 different mutations. Most of these mutations are frequent in 
Spain, Italy, and Portugal, and so is consistent with the origin of the European settlers. A 
few mutations found among Africans are also present in those countries which were part 
of the slave trade. This may be the result of the miscegenation of these populations. New 
mutations were also found which possibly originated in America (Pérez et al., 2007). As 
in most countries, F508del was the most common mutation detected, but in a lower 
proportion than the average frequency of 45–46% published for Latin-American 
countries (Keyeux et al., 2003; Pérez et al., 2007; Zielenski & Tsui, 1995), and the reported 
worldwide frequency of 66% (Lay-son et al., 2010; Zielenski & Tsui, 1995). The G542X 
mutation is the second most frequent mutation in Latin America, with a total frequency 
of 5.07%. N1303K, W1282X and R1162X are the next most frequent mutations, with 
variations from 0.59% to 3.95%. The frequency of the rest of the mutations varies from 
one country to another, but their overall frequencies are less than 1%, and could be 
considered to be rare in Latin America (Pérez et al., 2007). The carrier-rate and mutation-
frequencies vary widely in different populations, and so screening tests with high 
detection-rates for CFTR mutations have to consider the population’s ethnicity (Pieri et 
al., 2007). 
There is increasing evidence that CFTR mutations may contribute etiologically to certain 
monosymptomatic disorders. Infertile men with isolate obstructive azoospermia may 
have mutations in the CFTR, many of which are rare in classical CF and not evaluated in 
most routine mutation screening. It was demonstrated that the routine mutation panel 
has failed to identify CFTR mutations and the IVS8-5T allele in 46% of CBAVD groups, 
50% of CUAVD groups, and 79% of idiopathic epididymal obstruction groups. These 
results demonstrate that routine testing for CFTR mutations for infertile men may miss 
mild or rare gene alterations. The DNA sequence method detects more CFTR mutations 
than common mutation panels. This represents a significant problem because advances 
in assisted reproduction have allowed infertile male patients to conceive, raising the 
concern of transmitting – when present – pathogenic CFTR mutations onto progeny. The 
importance of accurate CFTR mutation detection in men with obstructive azoospermia 
and their partners has already been highlighted (Danzinger et al., 2004; Mak et al., 1999). 
Today, screening for a panel of CFTR mutations is offered to infertile men prior to in 
vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI), and includes only the 
most common mutations found amongst the CF patients of European and North 
American origin. The atypical CBAVD phenotype, however, is caused by milder 
mutations, most of them very rare or even not yet described, and thus not included in 
the panel of CF mutations usually screened. It was proposed that only an extensive CFTR 
screening can detect rare mutations that are not found by conventional screenings and 
commercial tests, and can thus improve the diagnosis and care of CF and CAVD as well 
as the prevention of new cases through the use of reproductive technologies (Pieri et al., 
2007). 
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However, genetic testing should only be performed in the context of appropriate genetic 
counselling and laboratories should work in close association with clinical geneticists and 
reference laboratories so as to ensure that pertinent tests are performed and that proper 
information is provided to patients. There is no standard or preferred method, but 
laboratories should be aware of the limitations of their chosen method and they should 
know which mutations are not identified, whether the techniques are commercially 
available or else being developed within the laboratory. This means that individual 
laboratories should choose a method which is suited to their experience, workload, and 
scope of testing. In addition to the screen for frequent mutations, a complementary panel 
may be required to test population-specific mutations with a frequency above 1%. The 
knowledge of the ethnic or geographic origins of patients and their parents and 
grandparents is therefore important in order to determine the analysis to be performed 
(Dequeker et al., 2009). The knowledge of geographic or ethnic variations in the local 
population mutation-frequency is crucial so as to properly achieve effective genetic 
counselling and improve the cost-effectiveness of screening and diagnostic tests (Lay-son et 
al., 2011). 
2.4 Ethical implications of genetic testing 
According to the Patient Registry 2009 of the CF Foundation, USA there are growing 
numbers of CF adults 18 years of age and over. The percentage of CF patients aged 18 years 
or older has risen from 30% in 1990 to over 47% in 2009. It also have indicated that the 
median age of survival of patients with CF has risen from 27 years in 1985 to almost 36 years 
in 2009,  leading to greater concern for the disease management of CF adults (Cystic Fibrosis 
Foundation Patient registry 2009: Annual data report, 2011). Coupled with an improved life 
expectancy, adult CF patients are more likely to seek independence from their families and 
pursue typical adult activities, such as attending college, entering serious relationships and 
pursuing careers (Modi et al., 2010). Issues related to sexual maturation, fertility, pregnancy 
and contraception have thus become important in the comprehensive care of CF patients 
(Tizzano et al., 1994). Fertility bears centrally to reproductive decision-making, determining 
whether natural conception is even an option or whether adoption or assisted reproductive 
technology must be considered (Hull & Kass, 2000). Along with the wish to conceive, CF 
parents and physicians confront major ethical issues regarding abortions, the premature 
termination of pregnancies, and possible arrangements in the event of morbidity or 
maternal mortality which should all be discussed prior to pregnancy (Barak et al., 2005). 
There are still many paediatric CF clinics that continue to care for patients up to 18 years of 
age. Several studies have suggested that teenage patients and their parents have unmet 
information needs regarding the patient’s sexual health. Usually, unplanned sex tends to be 
done without protection. An important priority for the CF team is to try to ensure that 
women with CF are aware of the risks of unplanned pregnancy. Collaboration between the 
family planning clinician and the teenager’s CF physician is recommended (Roberts & 
Green, 2005). As such, reproductive counselling and reproductive health issues must be 
carefully addressed to CF adult patients (Hull & Kass, 2000; Sawyer, 1996). CF healthcare 
providers are an important source of information, and early discussion of sexual and 
reproductive health is indicated in paediatric settings for the adolescent patients, since a 
very high interest in future parenting is expressed by CF men. It has been suggested that 
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there should be greater emphasis on infertility, semen analysis, and the prevention of 
sexually transmitted infections, backed with a greater focus on reproductive options within 
adult healthcare services (Sawyer et al., 2005). 
In the 1980s, it was thought to be too risky for a woman with CF to get pregnant and that it 
was impossible for a man with CF to father a child. Nowadays, improvements in the 
nutrition and lung function of these patients make it possible for CF women to have a 
healthy pregnancy and baby. In 2009, the Patient Registry reported that 226 women with CF 
were pregnant. Successful outcomes can be achieved for both the CF mother and the child 
with careful patient assessment, combined with the integration of a multidisciplinary team, 
composed of the CF physician, the fertility specialist and the obstetrician (CF Foundation 
Patient registry 2009: Annual data report, 2011). Close follow-up of the maternal and foetal 
condition, along with careful monitoring of ventilation, immunology, diabetes, glucose 
tolerance and nutrition is important since all these parameters may be adversely affected in 
a CF pregnancy (Barak et al., 2005; Rodgers et al., 2000). 
For CF men, advances in fertility medicine have given them the option to father children (CF 
Foundation Patient registry 2009: Annual data report, 2011). The use of assisted 
reproductive techniques (such as testicular micro-aspiration and intracytoplasmic sperm 
injection (ICSI)) has enabled testicular spermatozoa to fertilise ova without the need to be 
capacitated, or to undergo acrosome reaction or else penetrate and fuse it with the egg 
(Wong, 1998). A report on CF men that have undergone ICSI coupled with IVF showed that 
62% of the couples successfully achieved pregnancy (McCallum et al., 2000). A group of CF 
azoospermia males were submitted to ICSI and 63% of the couples had clinical pregnancy 
(Hubert et al., 2006). However, before such measures are taken, genetic screening and 
counselling for the men and their partners should be mandatory in safeguarding their 
offspring from the risk of clinical CF (DeBraekeleer and Férec, 1996). Moreover, CF men 
should be informed about their own health and any long-term issues (such as the likelihood 
of premature death) and this information should be clearly shared with their partner 
(Hubert et al., 2006). In the case of CBAVD patients – a genital form of CF – most carry a 
severe CF-causing CFTR mutation and, therefore, have a 0.5% chance of transmitting the 
CFTR mutation to the child. Assuming a risk of 1/25 of the partner being a CF carrier, and 
that a carrier has a chance of 0.5% of transmitting the mutant CFTR to the child, the 
combined risk of CBAVD couples of having a CF child is 1/100 when compared with a risk 
of 1/2500 amongst general population (Radpour et al., 2008). The detection of a CFTR 
mutation in CF male patients and their spouses is crucial, since the presence of a CFTR 
mutation would present a high-risk situation whereas its absence would present a low-risk 
situation (DeBraekeleer and Férec, 1996). In cases of oligozoospermia, it is also ideal to 
screen both partners. It was also recommended that – if resources are stretched – amongst 
couples with a CBAVD male only the female needs to be routinely CF screened because, if 
she is negative, then the couple's residual risk of having a CF or CBAVD child will be 
reduced to 1:960 (Lewis-Jones et al., 2000). The reproductive options for the majority of CF 
men who are infertile include not having children, adoption, in vitro fertilisation with donor 
sperm, and microscopic epididymal sperm aspiration (MESA) coupled with in vitro 
fertilisation.  There is also a complementary option, namely pre-implantation genetic 
diagnosis (PGD). PGD refers to the genetic testing of embryos created through IVF for the 
purpose of selecting embryos that would lead to the birth of a child unaffected by a 
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detectable genetic defect. The notion of preventing a disease by preventing the birth of an 
individual with that disease is controversial. The CFF has no official position on this 
practice, and this type of decision is a personal choice to be made by the individual together 
with his/her physician (Davis et al., 2010). 
3. Conclusion 
The National Institutes of Health, USA recommends genetic counselling for any couple 
attempting assisted reproductive techniques where the man has CF or obstructive 
azoospermia and is positive for a CFTR mutation. It is important to analyse the clinical 
genetic conditions of the families by evaluating the full family history, by documenting the 
pregnancy and foetal, neonatal, and paediatric loss of life, as well as by cytogenetic studies 
of the couple and analysis for CFTR mutations. At this time, it is debatable whether it is 
better to perform the screening for mutations in the full gene or whether it is better to 
screening for typical local mutations of a population. It is also subject of debate if it is better 
to perform the screening for mutations in CF affected individuals only or also in their 
partner. All these choices have ethical and social implications and there may be better 
resolution with new population studies focused on the frequency of mutations in CF 
individuals with infertility. CF is now a disease of the adult population with many adult-
specific issues. As such, adult CF patients must be treated by a well-trained interdisciplinary 
team of adult-care providers within the environment of the CF care network. 
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